Effect of topical mitomycin C on corneal endothelium

Area of Science:

• Ophthalmology
• Corneal Disease
• Ophthalmic Oncology

Background:

• Ocular surface squamous neoplasia (OSSN) is a pre-malignant or malignant epithelial tumor.
• Topical mitomycin C (MMC) is a chemotherapeutic agent used in ophthalmic practice.
• The effects of topical MMC on corneal parameters require thorough evaluation.

Purpose of the Study:

• To assess the impact of topical mitomycin C (MMC) on corneal thickness and endothelial cell density in patients with OSSN.
• To evaluate the safety profile of topical MMC concerning corneal health.

Main Methods:

• A prospective, nonrandomized, interventional study.
• 25 patients with OSSN were treated with topical MMC 0.04% cyclically.
• Corneal thickness and endothelial cell counts were measured pre-treatment and post-resolution, with fellow eyes serving as controls.

Main Results:

• No statistically significant changes were observed in corneal thickness (pachymetry) after topical MMC treatment.
• Endothelial cell density remained largely unchanged in the treated eyes compared to baseline and control eyes.
• The study found no significant adverse effects on corneal endothelium from topical MMC application.

Conclusions:

• Topical 0.04% MMC eye drops demonstrate a favorable safety profile regarding corneal endothelium.
• Judicious use and long-term follow-up are recommended for patients undergoing topical MMC treatment for OSSN.
• Topical MMC can be considered a safe therapeutic option for OSSN with respect to corneal integrity.